NCT06937203View on ClinicalTrials.gov

Study of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

May 7, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
ObesityDiabetes Mellitus, Type 2
Interventions
DRUG

ARO-ALK7

SC injection

DRUG

Placebo

calculated volume to match active treatment by SC injection

Trial Locations (1)

1010

RECRUITING

Research Site, Auckland

Sponsors
All Listed Sponsors
lead

Arrowhead Pharmaceuticals

INDUSTRY